Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Development of Glypican-2 redirected T cells for the Treatment of Neuroblastoma

Award Number: F31CA250401
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS
PERIOD OF PERFORMANCE START DATE: 01/01/2021
PERIOD OF PERFORMANCE END DATE: 12/31/2022

Group Awards By:

View Award Description

Development of Glypican-2 redirected T cells for the Treatment of Neuroblastoma - Project Summary The objective of this proposal is to develop a T cell-based immunotherapy for the treatment of high-risk neuroblastoma (NB), for which outcomes remain poor. The adoptive transfer of chimeric antigen receptor (CAR) T cells specific for CD19 has been highly effective for CD19+ hematological malignancies. However, the efficacy of CAR T cells for the treatment of solid tumors, including NB, has been limited. Glypican 2 (GPC2) is a promising CAR target for NB since it is closely linked to its malignant phenotype. I have successfully generated a GPC2- CAR with a 41BBζ signaling domain and have shown in preliminary studies that T cells expressing this CAR (GPC2.41BBζ-CAR T cells) recognize and kill GPC2+ NB cells. In this project I now propose to optimize the effector function of GPC2.41BBζ-CAR T cells. Optimal CAR T cell activation and expansion requires a distinct set of signals, which consist of antigen-specific CD3ζ activation (signal 1) and costimulation (signal 2). Upon proper costimulation, T cells produce cytokines (signal 3), which is critical for their expansion. We and other investigators have shown that CAR T cells have a limited ability to sequentially eradicate tumor cells. In this application I therefore propose to investigate if provision of signal 3 or improving signal 1 enhances the antitumor activity of GPC2.41BBζ-CAR T cells. Specifically, I hypothesize that provision of signal 3 via transgenic expression of IL-15 or improving signal 1 by knocking out the negative regulator Src homology domain 2-containing phosphatase-1 (SHP-1) will bolster the antitumor activity of GPC2-CAR T cells for the treatment of NB. This hypothesis will be tested in two interrelated research aims. Aim 1 compares the effector function of GPC2.41BBζ-CAR and IL-15 secreting GPC2.41BBζ-CAR T cells, and Aim 2 will determine whether CRISPR/Cas9-mediated knockout of SHP-1 improves the effector function of GPC2.41BBζ-CAR T cells. State- of-the-art immunological assays will be utilized in both aims including phenotypic analysis, and their ability to kill tumor cells, expand, and produce cytokines after repeated exposure to tumor cells. Additionally, these CAR T cells will be compared in vivo to assess their ability to expand, persist, and eliminate established tumors. This project was carefully designed to provide me with a training opportunity to familiarize myself with the rapidly evolving field of cellular immunotherapy for cancer and state of the art techniques to characterize tumor-specific T cells. At the conclusion of the grant I expect to have optimized GPC2-CAR T cells for future clinical testing in patients with recurrent/refractory NB.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2024 ( Subtotal = -$2,465 )
2024	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL # 1500	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	000	2	10/31/2023	NON-COMPETING CONTINUATION	-$2,465
														Subtotal = -$2,465

Issue Date FY: 2022 ( Subtotal = $42,753 )
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	000	2	12/21/2021	NON-COMPETING CONTINUATION	$42,036
2022	2022	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	001	2	4/29/2022	NON-COMPETING CONTINUATION	$717
														Subtotal = $42,753

Issue Date FY: 2021 ( Subtotal = $42,036 )
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	002	1	2/1/2021	NEW	$0
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	001	1	2/1/2021	NEW	$516
2021	2021	ST. JUDE CHILDREN'S RESEARCH HOSPITAL GRADUATE SCHOOL OF BIOMEDICAL SCIENCES, LLC	262 DANNY THOMAS PL	MEMPHIS	TN	38105	SHELBY	USA	Cancer Research Manpower	000	1	12/10/2020	NEW	$41,520
														Subtotal = $42,036

Grand Total All Awards = $82,324

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Development of Glypican-2 redirected T cells for the Treatment of Neuroblastoma

Award Number: F31CA250401

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: FELLOWSHIP/SCHOLARSHIP/STUDENT LOANS

PERIOD OF PERFORMANCE START DATE: 01/01/2021

PERIOD OF PERFORMANCE END DATE: 12/31/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer